Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.11038
Abstract: 11038Background: We retrospectively collected data from metastatic Italian GIST patients treated with imatinib or sunitinib reintroduction after progression to conventional three or four lines of t... read more here.
Keywords: sunitinib regorafenib; imatinib sunitinib; advanced gist; gist progressing ... See more keywords
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.tps767
Abstract: TPS767 Background: Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal sarcoma with approximately 80% of cases driven by KIT mutations. Most patients (pts) with advanced GIST experience disease progression following first-line treatment with imatinib… read more here.
Keywords: exon mutations; kit; advanced gist; ripretinib sunitinib ... See more keywords
The efficacy and safety of radiotherapy combined with tyrosine kinase inhibitors in the treatment of advanced GIST.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e23519
Abstract: e23519 Background: Phase II multicenter study (identifier NCT00515931) have found that gastrointestinal stromal tumor (GIST) is moderately sensitive to radiotherapy, and we have applied this treatment for patients with advanced GIST. Methods: Patients with GIST… read more here.
Keywords: treatment; radiotherapy; tyrosine kinase; efficacy ... See more keywords